GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world's poorest countries
LONDON, United-Kingdom, May 9, 2013/African Press Organization (APO)/ -- GlaxoSmithKline (GSK) (http://www.gsk.com) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world's poorest countries. To start the program and over the next two years, GSK will supply doses of Cervarix® (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at $4.60 per dose.
Logo GSK: http://www.photos.apo-opa.com/plog-content/images/apo/logos/glaxosmithkline.jpg
Christophe Weber, President and General Manager, GSK Vaccines said: “Cervical cancer is a significant issue especially in poorer countries where the availability of screening is limited. We are pleased to be expanding our commitment to GAVI by delivering our Cervarix® vaccine to help protect girls in the developing world. This continues our significant commitment to make our vaccines accessible to as many people as possible, no matter where in the world they live. We hope that this will help reduce the burden of cervical cancer and positively impact future generations.”
“A vast gap currently exists between girls in rich and poor countries. With GAVI's programmes we can begin to bridge that gap so that all girls can be protected against cervical cancer no matter where they are born,” said Dr Seth Berkley, CEO of the GAVI Alliance. “By 2020 we hope to reach more than 30 million girls in more than 40 countries. This is a transformational moment for the health of women and girls across the world. We thank the manufacturers for working with us to help make this happen.”
The approved GAVI demonstration programmes will begin over the coming months and will help build vital experience in delivering cervical cancer vaccines to girls aged 9 years and over. The demonstration programmes will enable the countries to evaluate their ability to roll out national immunisation programmes.
GSK currently supplies more than 80% of its total vaccine volumes to developing countries and is a long-standing partner with GAVI. This latest commitment adds to existing agreements to supply up to 480 million doses of our pneumococcal vaccine to GAVI over the next 10 years and 132 million doses of our rotavirus vaccine to GAVI over the next five years.
Distributed by the African Press Organization on behalf of GlaxoSmithKline (GSK).
Media contact
Deanna Petersen
on behalf of GlaxoSmithKline
Tel: +27 79 702 8033
GSK's commitment to GAVI-eligible countries
• GSK has a long relationship with GAVI and has agreements in place to provide Rotarix™ (rotavirus vaccine, live, attenuated) and Synflorix™ (pneumococcal polysaccharide conjugate vaccine (adsorbed)) to GAVI at significantly reduced prices to help accelerate access to vaccines in developing countries
• GSK is widely recognised for having sustainable access strategies for our vaccines and was again named number one on the Access to Medicines Index in 2012
About cervical cancer
Cervical cancer is a significant problem in developing countries and it is estimated that, by 2030, 474,000 women per year will die of cervical cancer.(1) Worldwide, cervical cancer is the second most common cancer in women with an estimated 529,000 new cases and 275,000 deaths in 2008.(2) More than 85% of this global disease burden occurs in developing countries.(2) With population growth and ageing, the number of cervical cancer cases is expected to increase 1.5 fold by 2030.(3)
About Cervarix®
• Cervarix® is a vaccine that helps protect girls and women against cervical cancer(4)
• In clinical trials, the most common adverse events after vaccination with Cervarix® were injection site reactions (such as pain, redness, swelling), headache, muscle pain and fatigue(4)
• Since its launch in 2007, Cervarix® has become available in 126 high, middle and low income countries around the world(5)
• In 2009, Cervarix® was awarded prequalification status by the World Health Organization enabling UN agencies and the GAVI Alliance to purchase the vaccine in partnership with developing countries at affordable prices
• To date, over 36 million doses of Cervarix® have been distributed(5)
• The vaccine is manufactured at GSK Vaccines HQ in Wavre, Belgium
• Cervarix® is a registered trademark of the GlaxoSmithKline group of companies and Rotarix™ and Synflorix™ are trademarks of the GlaxoSmithKline group of companies. Summary of Product Characteristics for Cervarix® can be found here: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf
GlaxoSmithKline (http://www.gsk.com) – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com
GlaxoSmithKline Enquiries:
UK Media enquiries:
David Mawdsley +44 (0) 20 8047 5502 (London)
David Daley +44 (0) 20 8047 5502 (London)
Catherine Hartley +44 (0) 20 8047 5502 (London)
US Media enquiries:
Stephen Rea +1 215 751 4394 (Philadelphia)
Kevin Colgan +1 919 483 2933 (North Carolina)
Melinda Stubbee +1 919 483 2510 (North Carolina)
Mary Anne Rhyne +1 919 483 0492 (North Carolina)
Sarah Alspach +1 202 715 1048 (Washington, DC)
Jennifer Armstrong +1 215 751 5664 (Philadelphia)
Analyst/Investor enquiries:
Ziba Shamsi +44 (0) 20 8047 3289 (London)
Lucy Budd +44 (0) 20 8047 2248 (London)
Tom Curry +1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 5503 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.
References
1. Progress in Cervical Cancer Prevention: The CCA Report Card. August 2011. Available at: http://www.cervicalcanceraction.org/pubs/CCA_reportcard_med-res.pdf [Last accessed: February 2013]
2. GLOBOCAN 2008: IARC Cancer Fact Sheets: Cervical Cancer. Available at: http://globocan.iarc.fr/factsheets/cancers/cervix.asp [Last accessed: February 2013]
3. Broutet N. Interventions for encouraging sexual behaviours intended to prevent cervical cancer [Last revised: 1 April 2012]. The WHO Reproductive Health Library; Geneva: World Health Organization. Available at: http://apps.who.int/rhl/gynaecology/cancer/cd001035_broutetn_com/en/index.html [Last accessed: April 2013]
4. Summary of Product Characteristics. Cervarix®. GlaxoSmithKline. EMA. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000721/WC500024632.pdf [Last accessed: February 2013]
5. GSK data on file